- Is The Cigna Group (CI) One of the Best Dividend Stocks to Buy for Steady Growth?
May 12, 2026
With a 5-year average dividend growth rate of 42.4%, The Cigna Group (NYSE:CI) is included among the 14 Best Dividend Stocks to Buy for Steady Growth.Is The Cigna Group (CI) One of the Best Dividend Stocks to Buy for Steady Growth?
On May 5, Bernstein analyst Lance Wilkes raised the firm’s price recommendation on The Cigna Group (NYSE:CI) to $371 from $358. It reiterated an Outperform rating following the company’s quarterly results. The firm said it is updating its earnings model, with EPS estimates remaining largely unchanged for 2026 and moving modestly higher for the 2027 through 2030 period.
During Cigna Group’s Q1 2026 earnings call, CEO and Chair David Cordani said the company delivered strong first-quarter results. Total revenue came in at $68.5 billion, while adjusted earnings per share reached $7.79. Cordani also said Cigna raised its full-year 2026 adjusted EPS guidance to at least $30.35.
He pointed to the company’s efforts to simplify healthcare processes in the U.S. According to Cordani, Cigna removed hundreds of tests, procedures, and services from the prior authorization process. Those changes reduced the volume of medical prior authorizations by around 15%. Cordani also highlighted the launch of the company’s rebate-free pharmacy service model as part of its broader transformation efforts. He said the new offering is called Signature.
The Cigna Group (NYSE:CI) is a global health company with two operating segments: Evernorth Health Services and Cigna Healthcare.
While we acknowledge the potential of CI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Best Inflation-Hedge Stocks to Buy for 2026 and 10 Best Stocks to Buy to Beat the S&P 500
Disclosure: None. Follow Insider Monkey on Google News.
View Comments
- Kayne Anderson Energy Infrastructure Fund Announces Appointment of Michael J. Hennigan as New Independent Director
May 12, 2026
Kayne Anderson Energy Infrastructure Fund, Inc.
HOUSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Kayne Anderson Energy Infrastructure Fund, Inc. (the “Company” or “KYN”) announced today the appointment of Michael J. Hennigan as an independent director of the Company, effective immediately. Following the retirements of William R. Cordes and Barry R. Pearl earlier this year, the appointment of Mr. Hennigan brings the Company’s Board to six members, five of whom are independent.
Michael J. Hennigan is a highly accomplished energy executive, with several decades of leadership experience in the refining and midstream sectors. Mr. Hennigan most recently served as Executive Chairman of Marathon Petroleum Corporation (NYSE: MPC) and MPLX LP (NYSE: MPLX) until his retirement in December 2025, having previously served as Chief Executive Officer of MPC and Chairman, President and Chief Executive Officer of MPLX.
Mr. Hennigan joined MPLX in 2017 and has held senior leadership roles spanning refining, logistics and midstream operations. Prior to joining MPLX, Mr. Hennigan was President of Crude, NGL and Refined Products of the general partner of Energy Transfer Partners, L.P. Mr. Hennigan began his career at Sunoco, Inc., where he spent more than three decades in roles of increasing responsibility, ultimately serving as President and Chief Executive Officer of Sunoco Logistics.
Mr. Hennigan currently serves on the boards of The Cigna Group (NYSE: CI) and Nutrien Ltd. (NYSE: NTR). He holds a Bachelor of Science degree in chemical engineering from Drexel University in Philadelphia.
“We are very pleased to welcome Mike to KYN’s Board of Directors,” said Jim Baker, Chairman, President, and CEO. “Mike brings a wealth of knowledge from his long career in the energy industry and extensive experience in the midstream sector. His perspective leading one of the largest and most complex energy platforms in North America will be an invaluable resource to our Board. As the energy and power infrastructure landscape continues to evolve, we believe Mike’s insights will further enhance our ability to capitalize on opportunities and deliver long-term value for KYN’s stockholders,” concluded Mr. Baker.
Kayne Anderson Energy Infrastructure Fund, Inc. (NYSE: KYN) is a non-diversified, closed-end management investment company registered under the Investment Company Act of 1940, as amended, whose common stock is traded on the NYSE. The Company’s investment objective is to provide a high after-tax total return with an emphasis on making cash distributions to stockholders. KYN intends to achieve this objective by investing at least 80% of its total assets in securities of Energy Infrastructure Companies. See Glossary of Key Terms in the Company’s most recent quarterly report for a description of these investment categories and the meaning of capitalized terms.
Story Continues
The Company pays cash distributions to common stockholders at a rate that may be adjusted from time to time. Distribution amounts are not guaranteed and may vary depending on a number of factors, including changes in portfolio holdings and market conditions.
This press release shall not constitute an offer to sell or a solicitation to buy, nor shall there be any sale of any securities in any jurisdiction in which such offer or sale is not permitted. Nothing contained in this press release is intended to recommend any investment policy or investment strategy or consider any investor’s specific objectives or circumstances. Before investing, please consult with your investment, tax, or legal adviser regarding your individual circumstances.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This communication contains statements reflecting assumptions, expectations, projections, intentions, or beliefs about future events. These and other statements not relating strictly to historical or current facts constitute forward-looking statements as defined under the U.S. federal securities laws. Forward-looking statements involve a variety of risks and uncertainties. These risks include but are not limited to changes in economic and political conditions; regulatory and legal changes; energy industry risk; leverage risk; valuation risk; interest rate risk; tax risk; and other risks discussed in detail in the Company’s filings with the SEC, available at www.kaynefunds.com or www.sec.gov. Actual events could differ materially from these statements or our present expectations or projections. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. Kayne Anderson undertakes no obligation to publicly update or revise any forward-looking statements made herein. There is no assurance that the Company’s investment objectives will be attained.
Contact investor relations at 877-657-3863 or cef@kayneanderson.com.
View Comments
- Chris Davis Significantly Reduces Stake in Applied Materials Inc, Impacting Portfolio by -3.47%
May 7, 2026
This article first appeared on GuruFocus.
Insight into Chris Davis (Trades, Portfolio)'s Strategic Moves in Q1 2026
Warning! GuruFocus has detected 4 Warning Sign with AIG. Is COF fairly valued? Test your thesis with our free DCF calculator.
Chris Davis (Trades, Portfolio) recently submitted the 13F filing for the first quarter of 2026, providing insights into his investment moves during this period. Davis Advisors manages more than $60 billion across several different asset classes. Chris Davis (Trades, Portfolio) is the portfolio manager of Davis Financial Fund. Davis purchases durable, well-managed businesses that can be purchased at value prices and held for the long term (average holding period of a stock in the Davis New York Venture Fund is four to seven years). Davis focuses primarily on financial services companies. He looks to buy companies when they are out of favor.
Key Position Increases
Chris Davis (Trades, Portfolio) also increased stakes in a total of 64 stocks, among them:
The most notable increase was The Cigna Group (NYSE:CI), with an additional 1,481,077 shares, bringing the total to 2,233,929 shares. This adjustment represents a significant 196.73% increase in share count, a 1.82% impact on the current portfolio, with a total value of $595,905,880. The second largest increase was JBS NV (NYSE:JBS), with an additional 14,389,919 shares, bringing the total to 26,244,660. This adjustment represents a significant 121.39% increase in share count, with a total value of $471,354,100.
Summary of Sold Out
Chris Davis (Trades, Portfolio) completely exited 2 of the holdings in the first quarter of 2026, as detailed below:
UDR Inc (NYSE:UDR): Chris Davis (Trades, Portfolio) sold all 113,280 shares, resulting in a -0.02% impact on the portfolio. Netstreit Corp (NYSE:NTST): Chris Davis (Trades, Portfolio) liquidated all 189,600 shares, causing a -0.02% impact on the portfolio.
Key Position Reduces
Chris Davis (Trades, Portfolio) also reduced positions in 36 stocks. The most significant changes include:
Reduced Applied Materials Inc (NASDAQ:AMAT) by 3,004,196 shares, resulting in a -71.51% decrease in shares and a -3.47% impact on the portfolio. The stock traded at an average price of $336.38 during the quarter and has returned 27.72% over the past 3 months and 60.29% year-to-date. Reduced Darling Ingredients Inc (NYSE:DAR) by 2,654,401 shares, resulting in a -93.39% reduction in shares and a -0.43% impact on the portfolio. The stock traded at an average price of $49.25 during the quarter and has returned 29.00% over the past 3 months and 72.72% year-to-date.
Story Continues
Portfolio Overview
At the first quarter of 2026, Chris Davis (Trades, Portfolio)'s portfolio included 112 stocks, with top holdings including 7.15% in Capital One Financial Corp (NYSE:COF), 5.99% in Coterra Energy Inc (NYSE:CTRA), 5.31% in U.S. Bancorp (NYSE:USB), 4.85% in Viatris Inc (NASDAQ:VTRS), and 4.52% in Meta Platforms Inc (NASDAQ:META).
The holdings are mainly concentrated in 10 of all the 11 industries: Financial Services, Healthcare, Communication Services, Consumer Cyclical, Energy, Technology, Consumer Defensive, Basic Materials, Industrials, and Real Estate.
View Comments
- Cigna Group's (NYSE:CI) Solid Earnings Are Supported By Other Strong Factors
May 7, 2026
Investors were underwhelmed by the solid earnings posted by The Cigna Group (NYSE:CI) recently. Our analysis says that investors should be optimistic, as the strong profit is built on solid foundations.
This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.NYSE:CI Earnings and Revenue History May 7th 2026
How Do Unusual Items Influence Profit?
For anyone who wants to understand Cigna Group's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit was reduced by US$1.8b due to unusual items. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And, after all, that's exactly what the accounting terminology implies. Assuming those unusual expenses don't come up again, we'd therefore expect Cigna Group to produce a higher profit next year, all else being equal.
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
Our Take On Cigna Group's Profit Performance
Because unusual items detracted from Cigna Group's earnings over the last year, you could argue that we can expect an improved result in the current quarter. Based on this observation, we consider it likely that Cigna Group's statutory profit actually understates its earnings potential! And the EPS is up 6.5% annually, over the last three years. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. Every company has risks, and we've spotted 1 warning sign for Cigna Group you should know about.
Today we've zoomed in on a single data point to better understand the nature of Cigna Group's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.
Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
View Comments
- The Cigna Group (CI) Price Target Boosted by $7 Following Better-than-Expected Q1
May 6, 2026
With an upside potential of 20.18% as of May 3, The Cigna Group (NYSE:CI) is included among the 10 Best Fortune 500 Stocks to Buy According to Analysts.The Cigna Group (CI) Price Target Boosted by $7 Following Better-than-Expected Q1
The Cigna Group (NYSE:CI) is a global health company that provides insurance and related products and services. It operates through two segments: Evernorth Health Services and Cigna Healthcare.
On May 1, Barclays increased its price target on The Cigna Group (NYSE:CI) from $303 to $310, while maintaining an ‘Overweight’ rating on the shares. The raised target, which represents an upside of almost 10% from the current levels, comes following the company’s Q1 report.
The Cigna Group (NYSE:CI) posted strong results for its first quarter on April 30, exceeding estimates in both profits and revenue. The company grew its adjusted EPS by around 16% YoY to $7.79, while its revenue of $68.5 billion was also up by 4.7% compared to last year. Notably, Cigna also revealed that it would exit subsidized plans offered under the Affordable Care Act, also known as Obamacare, at the end of this year.
The Cigna Group (NYSE:CI) also raised its full-year 2026 consolidated adjusted earnings per share outlook to at least $30.35, up from the prior guidance of $30.25 and slightly better than the consensus of $30.33.
While we acknowledge the potential of CI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Best Blue Chip Stocks to Invest In According to Billionaires and 10 Best Fortune 500 Dividend Stocks to Invest In Right Now
Disclosure: None. Follow Insider Monkey on Google News.
View Comments
- CVS Health Stock Jumps After Earnings. What’s Encouraging Wall Street.
May 6, 2026
CVS Health’s Aetna was the third-largest provider of Medicare Advantage plans in 2025, behind UnitedHealth Group and Humana.
Continue Reading
- CVS Has Two Hurdles to Clear in Earnings. Medicare Advantage Just Might Be the Lower One.
May 5, 2026
CVS Health’s Aetna was the third-largest provider of Medicare Advantage plans in 2025, behind UnitedHealth Group and Humana.
Continue Reading
- Why Cigna (CI) Shares Are Trading Lower Today
May 3, 2026
What Happened?
Shares of health insurance company Cigna (NYSE:CI) fell 2.5% in the afternoon session after the company announced it will exit the Affordable Care Act (ACA) marketplace in 2027, which overshadowed a strong first-quarter earnings report.
Despite the healthcare giant exceeding revenue and profit expectations and raising its annual forecast, investors focused on the decision to leave the ACA market. This move is set to affect approximately 369,000 health plan members across 11 states.
Adding to the concerns was weakness within Cigna's pharmacy benefit manager operations. An analyst from TD Cowen described this as the “only blemish” in an otherwise solid quarterly report, noting that similar challenges had been seen at competitor companies. The negative news sent shares lower as the market weighed the strategic shift and divisional headwinds against the positive financial results.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Cigna? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Cigna’s shares are not very volatile and have only had 4 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 6 months ago when the stock dropped 14.3% on the news that the company reported underwhelming third-quarter results.
Revenue grew 9.5% year-on-year to $69.75 billion, beating estimates by 3.6%. Adjusted earnings per share came in at $7.83, which was 2.5% ahead of the consensus forecast. However, the positive results were overshadowed by concerns about profitability and future growth. The company's operating margin declined to 3% from 4% a year ago, continuing a multi-year downward trend in profitability.
Additionally, while Cigna's full-year earnings guidance was in line with expectations, forecasts for revenue growth over the next 12 months point to a significant slowdown. This, combined with a slight dip in customer numbers from the previous quarter, likely prompted investors to look past the quarterly beat and focus on potential challenges ahead.
Cigna is up 1.8% since the beginning of the year, but at $284.11 per share, it is still trading 15.2% below its 52-week high of $335.18 from April 2025. Investors who bought $1,000 worth of Cigna’s shares 5 years ago would now be looking at an investment worth $1,127.
Story Continues
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
View Comments
- The The Cigna Group (NYSE:CI) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 2, 2026
Investors in The Cigna Group (NYSE:CI) had a good week, as its shares rose 2.6% to close at US$283 following the release of its first-quarter results. Results overall were respectable, with statutory earnings of US$6.26 per share roughly in line with what the analysts had forecast. Revenues of US$68b came in 3.5% ahead of analyst predictions. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.
We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.NYSE:CI Earnings and Revenue Growth May 2nd 2026
Following last week's earnings report, Cigna Group's 17 analysts are forecasting 2026 revenues to be US$282.9b, approximately in line with the last 12 months. Per-share earnings are expected to rise 6.2% to US$25.34. Yet prior to the latest earnings, the analysts had been anticipated revenues of US$281.8b and earnings per share (EPS) of US$24.18 in 2026. So the consensus seems to have become somewhat more optimistic on Cigna Group's earnings potential following these results.
Check out our latest analysis for Cigna Group
The consensus price target was unchanged at US$339, implying that the improved earnings outlook is not expected to have a long term impact on value creation for shareholders. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on Cigna Group, with the most bullish analyst valuing it at US$378 and the most bearish at US$290 per share. The narrow spread of estimates could suggest that the business' future is relatively easy to value, or thatthe analysts have a strong view on its prospects.
Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. It's pretty clear that there is an expectation that Cigna Group's revenue growth will slow down substantially, with revenues to the end of 2026 expected to display 2.4% growth on an annualised basis. This is compared to a historical growth rate of 12% over the past five years. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 4.7% annually. So it's pretty clear that, while revenue growth is expected to slow down, the wider industry is also expected to grow faster than Cigna Group.
Story Continues
The Bottom Line
The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around Cigna Group's earnings potential next year. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. The consensus price target held steady at US$339, with the latest estimates not enough to have an impact on their price targets.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have forecasts for Cigna Group going out to 2028, and you can see them free on our platform here.
However, before you get too enthused, we've discovered 1 warning sign for Cigna Group that you should be aware of.
Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
View Comments
- CI Q1 Deep Dive: Specialty Growth, Portfolio Reshaping, and New Pharmacy Model Drive Outlook
May 2, 2026
Health insurance company Cigna (NYSE:CI) announced better-than-expected revenue in Q1 CY2026, with sales up 4.7% year on year to $68.52 billion. Its non-GAAP profit of $7.79 per share was 2.4% above analysts’ consensus estimates.
Is now the time to buy CI? Find out in our full research report (it’s free).
Cigna (CI) Q1 CY2026 Highlights:
Revenue: $68.52 billion vs analyst estimates of $66.5 billion (4.7% year-on-year growth, 3% beat) Adjusted EPS: $7.79 vs analyst estimates of $7.61 (2.4% beat) Adjusted EBITDA: $3.15 billion vs analyst estimates of $3.21 billion (4.6% margin, 2% miss) Management slightly raised its full-year Adjusted EPS guidance to $30.35 at the midpoint Operating Margin: 3.4%, in line with the same quarter last year Customers: 16.62 million, up from 16.42 million in the previous quarter Market Capitalization: $76.61 billion
StockStory’s Take
Cigna’s first quarter results reflected momentum in its core health services and specialty pharmacy businesses, as management highlighted strong demand for specialty drugs and continued investment in technology. CEO David Cordani cited improvements in operational efficiency and customer-focused initiatives, such as streamlining prior authorizations and leveraging AI to enhance patient engagement. Specialty and Care Services, in particular, saw robust adoption of biosimilars and specialty generics, which management pointed to as key factors supporting margin stability and cost management. CFO Ann Dennison noted that lower flu volumes and weather-related care deferrals also contributed to favorable medical cost trends for the quarter.
Looking forward, Cigna’s updated guidance is underpinned by a sharpened focus on core health platforms, the roll-out of its rebate-free pharmacy benefits model called Signature, and continued investment in AI-driven personalization. Incoming CEO Brian Evanko emphasized the importance of scaling specialty services, expanding digital tools, and advancing affordability for both employers and patients. Management expects ongoing portfolio reshaping, including the exit from the individual exchange business and a strategic review of eviCore, to enable greater focus on high-growth segments. Evanko stated, “We are well positioned to lead the next era of consumer-focused and AI-enabled health services, emphasizing clinically complex patients and driving value for all stakeholders.”
Key Insights from Management’s Remarks
Management attributed the quarter’s performance to growth in specialty pharmacy, operational streamlining, and portfolio decisions aimed at focusing on higher-value segments.
Story Continues
Specialty pharmacy momentum: Cigna saw continued strength in its Specialty and Care Services segment, with management attributing this to growing demand for specialty medications, increased biosimilar adoption, and the integration of recent acquisitions like Shields Health Solutions and CarepathRx. These factors contributed to higher adoption rates and improved patient outcomes. AI and analytics integration: The company expanded its use of advanced analytics and artificial intelligence to personalize care, predict high-cost claimants, and streamline administrative tasks. Management noted that these efforts have led to measurable reductions in unnecessary emergency room visits and improved customer satisfaction, as evidenced by a 20-25% drop in call volumes among digitally engaged members. Portfolio reshaping: Cigna announced plans to exit the individual exchange health insurance market by the end of this year, citing limited scalability and a desire to intensify focus on core growth platforms. Additionally, it launched a strategic review of alternatives for its prior authorization and utilization management unit, eviCore, as industry standards evolve toward automation and transparency. Pharmacy benefit model transition: The forthcoming Signature model, a rebate-free pharmacy service, is designed to guarantee patients the lowest out-of-pocket cost on branded drugs. Management highlighted positive early feedback from clients and expects at least half of its pharmacy benefit services members to transition to this model by 2028, improving affordability and transparency for employers and patients. Cost management and care trends: The quarter benefited from lower-than-expected flu volumes and weather-driven care deferrals, which supported margin stability in the health insurance business. Management also pointed to a higher mix of bronze plan members, affecting medical cost ratios but not altering the full-year outlook.
Drivers of Future Performance
Cigna’s outlook centers on scaling specialty services, advancing digital and AI investments, and optimizing its business mix through ongoing portfolio actions.
Specialty segment expansion: Management expects sustained mid- to high-single-digit growth in specialty pharmacy, supported by rising biosimilar penetration, expanded hospital partnerships, and increased investment in infusion and specialty generics. These trends are anticipated to drive margin improvement and market differentiation. Signature model rollout: The transition to the rebate-free Signature pharmacy benefit is projected to address affordability challenges and regulatory pressures facing employers and plan sponsors. Early client feedback has been positive, and management aims for broad adoption by 2028, expecting this model to enhance transparency and predictability in drug spending. Portfolio focus and AI adoption: The exit from the individual exchange market and the eviCore strategic review are intended to concentrate resources on core growth platforms. Investments in AI and analytics are expected to further reduce administrative burden, personalize care, and support proactive health interventions, though management acknowledged that persistent medical cost trends and regulatory changes remain risks.
Catalysts in Upcoming Quarters
In the coming quarters, our analyst team will be tracking (1) the pace of client transitions to the Signature pharmacy benefit model and feedback on its impact, (2) progress on portfolio reshaping, specifically any developments regarding the eviCore strategic review and exit from the individual exchange market, and (3) ongoing adoption rates and profitability within the specialty pharmacy segment, especially biosimilars and partnerships with hospitals. We will also pay close attention to the impact of AI-driven tools on cost trends and customer retention.
Cigna currently trades at $287.51, down from $292.32 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free for active Edge members).
High Quality Stocks for All Market Conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
View Comments
